ClinicalTrials.gg
TerminatedNCT00427960Updated Dec 16, 2010Results posted

Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg

A Phase 4 interventional study of Dietary advice and rosuvastatin in Hypercholesterolaemia, sponsored by AstraZeneca. Terminated at 9 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to inadequate recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
47th of 57
55 · median 203
Started
2006
with 1 other
Phase 4
15 of 59
none open now
Registered
13th of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2006, is one of 15 in phase 4, and was the 13th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.

03

Conditions studied

  • Hypercholesterolaemia

Keywords

  • cholesterol
  • statin
  • Asian
  • LDL-cholesterol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self described Asian, first or second generation
  • Male or female > or = 18 years with primary hypercholesterolaemia.

Exclusion criteria

Exclusion Criteria:

  • Use of cholesterol lowering drugs from visit 1
  • Homozygous familial hypercholesterolaemia
  • Active arterial disease within 3 months of study entry
  • Poorly controlled diabetes
  • Uncontrolled hypothyroidism
  • Active liver disease
  • History of alcoh/drug abuse.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
55 participants (actual)

Study arms

  • Active comparator
    rosuvastatin

    rosuvastatin 5 mg

    Behavioral: Dietary advice · Drug: rosuvastatin

  • Active comparator
    atorvastatin

    atorvastatin 10 mg

    Behavioral: Dietary advice · Drug: atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)

    Calculated as LDL-C at Week 6 - LDL-C at Week 12\] \* 100

    Time frame: 6 weeks (baseline) and 12 weeks

Secondary outcomes

  1. The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L

    Time frame: 6 weeks (Baseline) and 12 weeks

  2. The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L

    Time frame: 6 weeks (baseline) and 12 weeks

  3. The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.

    Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.

    Time frame: 6 weeks (baseline) and 12 weeks

  4. The Percentage Change From Baseline(week6) in TC

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  5. The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  6. The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L

    Time frame: 6 weeks (baseline) and 12 weeks

  7. The Percentage Change From Baseline (Week 6)in Non-HDL-C

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  8. The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  9. The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  10. The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  11. The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  12. The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  13. The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio

    Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

    Time frame: 6 weeks (baseline) and 12 weeks

  14. The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.

    Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.

    Time frame: 6 weeks (baseline) and 12 weeks

07

Results

Posted Mar 22, 2010
Limitations and caveats
The study achieved only 8% of the randomised target number of patients and for this reason alone was terminated early. Planned statistical analyses could not be performed. No scientifically valid conclusions can be drawn from the limited study data.

Participant flow

Participants were recruited from 25 primary and secondary care centres in the United Kingdom. The first participant was enrolled on 20th December 2006 and the last participant entered the study on 16th November 2007.

Participant flow — Overall Study
MilestoneRosuvastatinAtorvastatin
Started3025
Completed2821
Not completed24
Withdrew: Adverse event20
Withdrew: Withdrawal by subject03
Withdrew: Other01

Outcome measures

PrimaryPercentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)

Calculated as LDL-C at Week 6 - LDL-C at Week 12\] \* 100

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in LDL-C
Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)
Percent Change in LDL-CRosuvastatinAtorvastatin
Percentage Change in Low Density Lipoprotein - Cholesterol (LDL-C)33.2836.92
SecondaryThe Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L
Time frame:
6 weeks (Baseline) and 12 weeks
Reported as:
Number · Percentage of Participants
The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L
Percentage of ParticipantsRosuvastatinAtorvastatin
The Percentage of Participants Reaching the General Medical Services (GMS) Contract Target of Total Cholesterol (TC) <5 mmol/L5064
SecondaryThe Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L
Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percentage of Participants
The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L
Percentage of ParticipantsRosuvastatinAtorvastatin
The Percentage of Participants Reaching the Joint British Societies' Guideline (JBS 2) Targets of TC <4 mmol/L and LDL-C <2 mmol/L1628
SecondaryThe Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.

Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percentage of Participants
The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.
Percentage of ParticipantsRosuvastatinAtorvastatin
The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category, and the Combined LDL-C and TC Target of LDL-C<2.5 or 3.0 mmol/L and TC<4.5 or 5.0 mmol/L, Both Depending on Risk Category.4348
SecondaryThe Percentage Change From Baseline(week6) in TC

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in TC
The Percentage Change From Baseline(week6) in TC
Percent Change in TCRosuvastatinAtorvastatin
The Percentage Change From Baseline(week6) in TC-23.03-26.88
SecondaryThe Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in HDL-C
The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)
Percent Change in HDL-CRosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6) in High-density Lipoprotein Cholesterol (HDL-C)4.463.15
SecondaryThe Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L
Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percentage of Participants
The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L
Percentage of ParticipantsRosuvastatinAtorvastatin
The Percentage of Participants Reaching the Joint British Societies Guideline (JBS 2) Target of TC <4 mmol/L1312
SecondaryThe Percentage Change From Baseline (Week 6)in Non-HDL-C

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in Non-HDL-C
The Percentage Change From Baseline (Week 6)in Non-HDL-C
Percent Change in Non-HDL-CRosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6)in Non-HDL-C-29.72-34.09
SecondaryThe Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in ApoB
The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)
Percent Change in ApoBRosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6) in Apolipoprotein-B (ApoB)-25.96-28.67
SecondaryThe Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in ApoA1
The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)
Percent Change in ApoA1RosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6) in Apolipoprotein-A1 (ApoA1)-0.551.89
SecondaryThe Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in LDL-C/HDL-C Ratio
The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio
Percent Change in LDL-C/HDL-C RatioRosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6)in LDL-C/HDL-C Ratio-34.75-38.45
SecondaryThe Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in TC/HDL-C Ratio
The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio
Percent Change in TC/HDL-C RatioRosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6) in TC/HDL-C Ratio-24.99-28.42
SecondaryThe Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in Non-HDL-C/HDL-C Ratio
The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio
Percent Change in Non-HDL-C/HDL-C RatioRosuvastatinAtorvastatin
The Percentage Change From Baseline(Week 6) in Non-HDL-C/HDL-C Ratio-31.05-35.48
SecondaryThe Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio

Derived according to the following formula: 100\*\[Lipid at week 12 - Lipid at week 6\]/Lipid at week 6

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percent Change in ApoB/ApoA1 Ratio
The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio
Percent Change in ApoB/ApoA1 RatioRosuvastatinAtorvastatin
The Percentage Change From Baseline (Week 6) in ApoB/ApoA1 Ratio-22.89-28.75
SecondaryThe Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.

Risk categories are: Symptomatic Asymptomatic, total risk \<5% Asymptomatic, total risk ≥5%, baseline LDL-C\<3 mmol/L and baseline TC\<5 mmol/L Asymptomatic, total risk ≥5%, baseline LDL-C ≥3 mmol/L or baseline TC ≥5 mmol/L Patients are defined as symptomatic if they meet at least 1 of the following criteria: History of cardiovascular disease Type II diabetes or diabetes of unknown type Baseline TC ≥8 mmol/l Baseline LDL-C ≥6 mmol/l Baseline systolic BP ≥180 mmHg Baseline diastolic BP ≥110 mmHg Total risk is derived from age, sex, TC, systolic BP and smoking status.

Time frame:
6 weeks (baseline) and 12 weeks
Reported as:
Number · Percentage of Participants
The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.
Percentage of ParticipantsRosuvastatinAtorvastatin
The Percentage of Participants Reaching the European (EAS) Targets of LDL-C<2.5 or 3.00 mmol/L, Depending on Risk Category.56.756.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin———
Atorvastatin———
Most frequent serious events
Most frequent serious events
EventRosuvastatinAtorvastatin
Cerebrovascular AccidentNervous system disorders1/300/30
Most frequent other events
Most frequent other events
EventRosuvastatinAtorvastatin
DizzinessNervous system disorders3/301/25
HeadacheNervous system disorders1/302/25

Baseline characteristics

Age Continuous
Age Continuous(years)RosuvastatinAtorvastatinTotal
Mean50 ± 1153 ± 1151.5 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)RosuvastatinAtorvastatinTotal
Female131124.0
Male171431.0
08

Study locations

9 sites
  • Research Site
    Allerton, United Kingdom
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Blackburn, United Kingdom
  • Research Site
    Bolton, United Kingdom
  • Research Site
    Crawley, United Kingdom
  • Research SIte
    Glasgow, United Kingdom
  • Research Site
    Newcastle, United Kingdom
  • Research SIte
    Sheffield, United Kingdom
  • Research SIte
    Slough, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2007
First posted
Jan 29, 2007
Start
Dec 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Mar 22, 2010
Last update
Dec 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00427960
Lead sponsor
AstraZeneca
First posted
Jan 29, 2007
Start date
Dec 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Mar 22, 2010
Last update
Dec 16, 2010

Study contacts

Rhiannon Rowsell, MD
study director · AstraZeneca
Shahid Ali, MD
principal investigator · Bradford PCT
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Atorvastatin

Start the discussion